Alzheimer Disease

Excellence Forums

Leaders in the field sharing authoritative insights and institutional best practices.
If approved, Biogen’s aducanumab would be the first FDA-approved drug for Alzheimer disease (AD) since 2003 and the first ever disease-modifying drug for AD. However, the development of aducanumab has been plagued by complexities and controversies which jeopardize its approval, writes Matthew Schrag, MD, PhD, from Vanderbilt University.
In this podcast, Neurology Learning Network's Alzheimer Disease Section Editor Daniel Claassen, MD, interviews Ryan Darby, MD, about atrophy network mapping, delusions and neuropsychiatric manifestations of Alzheimer disease, apraxia and free will, and more.
In this podcast, Neurology Learning Network's Alzheimer Disease Section Editor Daniel Claassen, MD, interviews David T. Jones, MD, about common ideas and misconceptions about the role of amyloid in Alzheimer disease (AD), assessing amyloid status among patients, areas of future research for the role of amyloid in neurodegeneration and AD, and more. A full transcript is provided.
In this podcast, Dr Brickman discusses his recent study, which demonstrated the prevalence of cerebrovascular disease among individuals with Down syndrome, and indicated that cerebrovascular disease may be a "core feature" of Alzheimer disease. A full transcript is provided.
Brain structural changes during preclinical Alzheimer disease appear to have a biphasic trajectory, according to new findings. Neurology Learning Network spoke with first author Victor Montal, PhD(c), MSc, about these findings and their implications.
David Holtzman, MD, talks about the established biomarkers for Alzheimer disease, potential biomarkers being investigated, and how long it may take for these biomarker tests to make it to the bedside.
In this podcast, Noam Alperin, PhD, from the University of Miami Miller School, talks about his research on the effect of sleep quality on cognitive function in elderly adults.
A new study suggests that late-onset unprovoked seizures of unknown etiology may be associated with a doubled risk of developing dementia among older veterans. Corresponding study author Ophir Keret, MD, answered our questions about these findings.
New findings suggest that tau-positron emission tomography signal can predict future brain atrophy in individuals in the early symptomatic stages of Alzheimer disease. The study’s lead author, Renaud La Joie, PhD, answers our questions about this new research.
In this podcast, Thomas Holland, MD, from Rush University, answers our questions about his team's latest research on the effect of flavonols on the risk for Alzheimer dementia, as well as his other research in this area.
A new study team evaluated whether midlife obesity is a cause of dementia and whether risk factors such as diet or physical inactivity were causes or consequences of the gradual onset of dementia. Lead author Sarah Floud, PhD, answered our questions here.